Document text
Principal Investigator: Iain Fraser
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2021
Award: $38,806
Funding agency: National Institute of Allergy and Infectious Diseases
Cells of the innate immune system, such as dendritic cells and macrophages, constantly patrol host mucosal surfaces and peripheral tissues for signs of infection or injury. Since many people infected with SARS-CoV-2 clear the virus without developing symptoms, aspects of the innate immune response may hold the key to defeating this virus and its variants. The potential for an adverse cytokine storm depends on the interaction of different cell types at the site of infection. This highlights the need to study the immune response to SARS-CoV-2 in a combined environment of both epithelial cells, which are the primary target of infection, and innate immune cells such as macrophages, which are crucial drivers of inflammation.
Since this project has been delayed awaiting BSL-3 lab access, we will first summarize our research plan. We propose to establish a co-culture assay which can measure both viral replication in human epithelial cells, an established CoV-2-permissive cell, and IL-6 expression from THP1 human macrophages. As both assay readouts will be FACS-based, this will permit used of a pooled CRISPR screening approach, which will be less labor intensive on a genome-wide scale and more feasible with available equipment in the NIAID BSL-3 lab.
Post-infection, we will sort CD32+ THP1 cells from CD324+ (E-cadherin) epithelial cells, and assay the cells for viral levels and IL-6 expression. Viral levels will be assayed using a fluorescent antibody to the spike protein, while IL-6 will be assayed by well-established lab protocols for intracellular cytokine staining. Our expectation is that the epithelial cells will be the primary target for CoV-2 infection, and THP1 the primary IL-6 producers. For this reason, we initially seek to identify regulators of IL-6 in THP1 cells, while limiting the study of host factors of SARS-CoV-2 infectivity to epithelial cells.
Once we have established the viral infection and IL-6 expression assays as FACS-based readouts, we will test the reproducibility of the screen assays with positive control genes targeted by specific CRISPR/Cas9 gRNAs. We expect the confirmed human receptor for CoV-2, ACE2, to be an appropriate positive control for viral infection and possibly also for the IL-6 response. We will optimize the viral infection time, multiplicity of infection (MOI), incubation period for golgi block, cell fixation, IL-6 staining conditions and FACS-sorting for both fluorescent virus infection levels and IL-6 expression.
Once the primary assay is established, we propose to use an NCATS-provided CRISPR-based lentiviral library in pooled format (Cellecta). THP1 cells and epithelial cells will be separately infected with lentivirus and drug-selected under BSL-2 conditions. To ensure an average of 1 gRNA per cell, we will use an MOI of 0.3 for the lentiviral infection. Control pools of lentivirus-infected THP1 and epithelial cells will be retained for the later sequencing step to identify gRNAs that are lost from the library pool due to effects on cell viability.
SARS-CoV-2 preparation and infection will be performed in the BSL-3 lab. As described earlier, we will screen epithelial cells and differentiated THP1 cells in a co-culture system by mixing the CRISPR library-infected cells in a 1:1 ratio. After infection with SARS-CoV-2, cells will be treated with golgi block, fixed with 4% PFA and stained for IL-6, CD32 and CD324 following the previously optimized protocols. We will follow standard operating procedures for BSL-3 CoV-2 work to permit the fixed cells to be FACS-sorted under BSL-2 conditions.
Assuming that epithelial cells are the primary viral target and THP1 the primary IL-6 producers, we will sort six populations of cells: Highest and lowest 20% of THP1 cells stained for IL-6 expression and intermediate 60% of IL-6 stained cells as control, and highest and lowest 20% of epithelial cells analyzed for viral fluorescence also with intermediate 60% of cells as control. Genomic DNA will be isolated, gRNA sequences amplified by PCR and deep sequencing will be used to identify gRNAs that are enriched in the high/low 20% sets compared to the intermediate 60%. We will repeat the screen in triplicate to identify gRNAs that appear consistently in the high/low 20% populations. Genes targeted by these gRNAs will be followed up as candidate hits.
In FY2021, we have completed pilot assays under BSL-2 conditions with the human coronavirus OC43. We have confirmed we can effectively FACS-separate the epithelial cells and macrophages after co-culture and viral infection, and that this system drives a strong macrophage IL-6 response. We have recently completed the training to gain access to the BSL-3 lab and are now optimizing the epithelial cell/macrophage co-culture conditions for efficient SARS-CoV2 infection.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><ACE2><Active Follow-up><Assay><B cell differentiation factor><B cell stimulating factor 2><B-Cell Differentiation Factor><B-Cell Differentiation Factor-2><B-Cell Stimulatory Factor-2><BCDF><BSF-2><BSF2><Bioassay><Biologic Assays><Biological Assay><Blood monocyte><Body Tissues><CD 32 Antigens><CD32><CD32 Antigens><COVID crisis><COVID epidemic><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID-19 assay><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infected patient><COVID-19 infection><COVID-19 pandemic><COVID-19 patient><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID19 assay><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 patient><COVID19 positive patient><COVID19 public health crisis><COVID19 therapy><COVID19 treatment><COVID19 virus><CRISPR><CRISPR editing screen><CRISPR library><CRISPR method><CRISPR methodology><CRISPR screen><CRISPR technique><CRISPR technology><CRISPR-CAS-9><CRISPR-based library><CRISPR-based method><CRISPR-based screen><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 library><CRISPR/Cas9 screen><CRISPR/Cas9 technology><Cadherin-1><Cas nuclease technology><Cell Body><Cell Death><Cell Differentiation><Cell Differentiation process><Cell Survival><Cell Viability><Cells><Cellular Assay><Cessation of life><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats library><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Co-culture><CoV emergence><CoV-2><CoV2><Cocultivation><Coculture><Coculture Techniques><Coon's Technic><Coon's Technique><Cytokines and Inflammatory Response><Death><Dendritic Cells><Disease><Disorder><Drugs><E-Cadherin><Ensure><Environment><Epithelial Calcium-Dependent Adhesion Protein><Epithelial Cells><Epithelial-Cadherin><Equipment><Extracellular Space><Fc gamma RII><Fluorescence><Fluorescent Antibody Technic><Fluorescent Antibody Technique><Fluorescent Antinuclear Antibody Test><Gene Targeting><Genes><Genetic Screening><Genomic DNA><Goals><Golgi><Golgi Apparatus><Golgi Complex><Guide RNA><HCoV><HPGF><Hepatocyte-Stimulating Factor><Host Factor><Host Factor Protein><Human><Hybridoma Growth Factor><IFN-beta 2><IFNB2><IL-6><IL6 Protein><Immune><Immune response><Immunes><Immunofluorescence Technic><Immunofluorescence Technique><Immunological response><Infection><Inflammation><Inflammatory><Inflammatory Response><Inflammatory Response Pathway><Injury><Innate Immune Response><Innate Immune System><Integration Host Factors><Intercellular Space><Interleukin-6><Lentivirinae><Lentivirus><Libraries><Lung><Lung Respiratory System><MGI-2><Marrow monocyte><Measures><Medication><Modern Man><Mucosa><Mucosal Tissue><Mucous Membrane><Myeloid Differentiation-Inducing Protein><Mφ><NIAID><National Institute of Allergy and Infectious Disease><Peripheral><Pharmaceutic Preparations><Pharmaceutical Preparations><Plasmacytoma Growth Factor><Population><Preparation><Procedures><Proteins><Protocol><Protocols documentation><Receptor Protein><Reproducibility><Research><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 assay><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Site><Sorting - Cell Movement><Staining method><Stains><Surface><Symptoms><System><Testing><Time><Tissues><Training><Uvomorulin><Variant><Variation><Veiled Cells><Viral><Viral Diseases><Virion><Virus><Virus Diseases><Virus Particle><Virus Replication><Virus-Lenti><Work><Wuhan coronavirus><active followup><adverse consequence><adverse outcome><angiotensin converting enzyme 2><angiotensin converting enzyme II><base><cell assay><cell fixation><cell type><clustered regularly interspaced short palindromic repeats screen><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus emergence><coronavirus disease 2019 assay><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus emergence><coronavirus patient><cytokine><cytokine release syndrome><cytokine storm><deep sequencing><drug/agent><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><expectation><fluorescent antibody><follow up><follow-up><followed up><followup><gDNA><gRNA><genome scale><genome-wide><genomewide><hCoV19><host response><human CoV><human corona virus><human coronavirus><immune system response><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><injuries><interferon beta 2><macrophage><monocyte><nCoV><nCoV2><necrocytosis><new CoV><new corona virus><new coronavirus><novel CoV><novel corona virus><novel coronavirus><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><pulmonary><receptor><recruit><response><screening><severe acute respiratory syndrome coronavirus 2 assay><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><sorting><therapeutic target><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><viral infection><viral multiplication><viral replication><virus infection><virus multiplication><virus-induced disease>